Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16229229 | 0.89 | MAPT (0.31) | ABL1RIN1 | |
| SCHEMBL19754075 | 0.86 | CA1 (0.32) | ROCK2 | |
| SCHEMBL19754061 | 0.80 | LMNA (0.36) | POLB | |
| SCHEMBL9048607 | 0.80 | P2RY2 (0.38) | ROCK2P2RY2P2RY4P2RY6 | |
| SCHEMBL19981007 | 0.78 | P2RY6 (0.34) | ROCK2ABL1RIN1POLBP2RY2 | |
| SCHEMBL20459987 | 0.78 | P2RY6 (0.34) | ROCK2ABL1RIN1POLBP2RY2 | |
| SCHEMBL1937265 | 0.78 | P2RY6 (0.34) | ROCK2ABL1RIN1POLBP2RY2 | |
| SCHEMBL14946367 | 0.78 | P2RY6 (0.34) | ROCK2ABL1RIN1POLBP2RY2 | |
| SCHEMBL10459464 | 0.78 | P2RY6 (0.34) | ROCK2ABL1RIN1POLBP2RY2 | |
| SCHEMBL20215740 | 0.78 | P2RY6 (0.34) | ROCK2ABL1RIN1POLBP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170368177-A1 | NOVEL PEG DERIVATIVE | DELTA-FLY PHARMA, INC. (JP) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368177-A1 | NOVEL PEG DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNH, TPD52L2 | ROCK2 699/4885ABL1 1583/4885RIN1 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.